News Lookbook Collaborate Salaries Per Diem Marketplace Tools Referrals

B-Seen

The eye care industry's career marketplace — free for job seekers and independent practices.

Professionals

Find a Job
Create Profile
Lookbook
Collaborate

Pay & Career

Salary Transparency
Methodology
Career Tools
Field of View News

Employers

Post a Job
Corporate Partners
Pricing
Equipment Marketplace

Connect

About Us
Contact

Privacy Terms Cookies Accessibility Privacy Requests

B-Seen is operated by B-SEEN, LLC, 300 Needham St, Suite 4, Newton, MA, USA.

B-Seen

The eye care industry's career marketplace — free for job seekers and independent practices because the cost of hiring shouldn't be a barrier for the small, doctor-owned offices that are the backbone of eye care.

Professionals

Find a Job
Create Profile
Lookbook
Collaborate

Pay & Career

Salary Transparency
Methodology
Career Tools
Field of View News

Employers

Post a Job
Corporate Partners
Pricing
Equipment Marketplace

Connect

About Us
Contact

Privacy Terms Cookies Accessibility Privacy Requests

B-Seen is operated by B-SEEN, LLC, 300 Needham St, Suite 4, Newton, MA, USA. Contact: legal@b-seen.io

FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva | Field of View | B-Seen

Article

Back to Feed

FDA Approvals

FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva

FDA2d ago1 min read

FDA has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP).

Read full article on FDA

Discussion

No comments yet. Be the first to share your thoughts.